West Nile Virus Vaccine Design by T Cell Epitope Selection: In Silico Analysis of Conservation, Functional Cross-Reactivity with the Human Genome, and Population Coverage

Abstract EN

West Nile Virus (WNV) causes a debilitating and life-threatening neurological disease in humans.

Since its emergence in Africa 50 years ago, new strains of WNV and an expanding geographical distribution have increased public health concerns.

There are no licensed therapeutics against WNV, limiting effective infection control.

Vaccines represent the most efficacious and efficient medical intervention known.

Epitope-based vaccines against WNV remain significantly underexploited.

Here, we use a selection protocol to identify a set of conserved prevalidated immunogenic T cell epitopes comprising a putative WNV vaccine.

Experimentally validated immunogenic WNV epitopes and WNV sequences were retrieved from the IEDB and West Nile Virus Variation Database.

Clustering and multiple sequence alignment identified a smaller subset of representative sequences.

Protein variability analysis identified evolutionarily conserved sequences, which were used to select a diverse set of immunogenic candidate T cell epitopes.

Cross-reactivity and human leukocyte antigen-binding affinities were assessed to eliminate unsuitable epitope candidates.

Population protection coverage (PPC) quantified individual epitopes and epitope combinations against the world population.

3 CD8+ T cell epitopes (ITYTDVLRY, TLARGFPFV, and SYHDRRWCF) and 1 CD4+ epitope (VTVNPFVSVATANAKVLI) were selected as a putative WNV vaccine, with an estimated PPC of 97.14%.